GeNeuro’s ProTEct-MS Phase 2 trial data, presented at the ECTRIMS 2022 Congress in Amsterdam, confirms synergistic neuroprotective potential of temelimab in MS
Geneva, Switzerland, October 28, 2022 – 7:30 am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping causal factors driving the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announced that the primary analysis […]